NEW PRODUCTS

by Megan Silveira, assistant editor

Fight Respiratory Viruses and Improve Efficiency

Intranasal respiratory vaccine and feed additive to improve feed efficiency launched.

Nasalgen 3

Nasalgen® 3 was introduced by Merck Animal Health at the end of April. This three-way intranasal vaccine protects beef and dairy cattle from a variety of common pneumonia-causing viral pathogens.

"Nasalgen 3 mimics natural exposure to the most common pneumonia viruses," says Scott Nordstrom, veterinarian and associate director of ruminant life cycle management, Merck Animal Health. "The intranasal administration of Nasalgen 3 stimulates a strong, early immune

response because the vaccine antigens are delivered to mucosal surfaces in the nose — an area loaded with immunologically active tissues."

Nasalgen 3 has a


duration of six and a half months of immunity against infectious bovine rhinotracheitis (IBR), 11 weeks against bovine respiratory syncytial virus (BRSV) and three months against parainfluenza-3 (Pl.).

This vaccine avoids interference from maternal antibodies in colostrum capable of blocking injectable vaccines, and is not temperature sensitive.

For more information visit www. merck-animal-health-usa.com.

Optigrid 45 receives FDA approval

Global animal health company Huvepharma received FDA



to help promote weight gain and improve feed efficiency in finishing feedyard cattle.

Optigrid includes the active ingredient ractopamine hydrochloride. When used as a complete feed, this ingredient can help promote increased carcass leanness in cattle.

"In today's challenging world, with the continued need for efficiency in beef production, we are pleased to bring further medicated feed additive options such as Optigrid 45 to the cattle industry," says Glen Wilkinson, president of Huvepharma, Inc. (U.S.).

The product is a bio-equivalent to Optaflexx® and can be fed as a complete feed or a top-dress feed for cattle in confinement for slaughter, during the last 28 to 48 days on feed prior to harvest.

As a bioequivalent, Optigrid® provides the same benefits of dosage, chemical identity, potency, quality and safety as the existing

ractopamine hydrochloride brand.

Wilkinson says this newly approved product is another option in the company's product line.

For more information visit <u>www.</u> <u>huvepharma.us</u>.

